Actavis (ICE:ACT) Signs Distribution Agreement With J&M Pharma Co. Ltd In South Korea

Actavis (ICE:ACT) Seoul, South Korea, 30 October 2008 -- Actavis, the international generic pharmaceutical company, has entered into an exclusive distribution agreement, for a number of generic products, with J&M Pharma, Co Ltd, a Korean owned and operated pharmaceutical company, headquartered in Seoul, Korea. The agreement is an important step in building Actavis' presence in the Korean generics market.

Actavis is one of the world's leading generic pharmaceutical companies specialising in the development, manufacture and sale of generic pharmaceuticals. Actavis has operations in 40 countries, with 11,000 employees. Actavis' products are already marketed in the Asia Pacific region, in markets including Singapore, Hong Kong, China, Australia, Indonesia, Taiwan, Malaysia and Vietnam.

Commenting on this partnership Thomas Runkel, Vice President of Actavis in the Asia Pacific region said: "The partnership with J&M is an important milestone for our entrance into the fast growing Korean market. We look forward to working with J&M to bring our extensive generic product portfolio of first class generics onto the Korean market fast."

Tae-Hwan Kim, President of J&M, said: "We are excited to enter into an exclusive distribution agreement with Actavis for selected generic products. We will strive to position Actavis as a trusted generic brand in the Korean market and make a success story with its esteemed products."

Andrew Suh, CEO of Cosmo USA IBRC, Inc. (www.cosmo-usa.com), a life science industry consulting company, served an integral role in bringing Actavis and J&M together for this opportunity.

More information about Actavis Group can be found at www.actavis.com

Enquiries: Actavis Asia/Pacific Thomas Runkel Vice President Tel: (+62) 218 710311 ext 222 E-mail: trunkel@actavis.com

Actavis Group Hjordis Arnadottir Director, External Communications Tel: (+354) 535 2300 / 840 7476 E-mail: harnadottir@actavis.com

Any statements contained in this press release that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



LINK: http://hugin.info/134004/R/1264872/278141.jpg



LINK: http://hugin.info/134004/R/1264872/278143.jpg

Actavis

http://www.actavis.com

ISIN: IS0000000420

Stock Identifier: ICEX.ACT